NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

Interesting, though I'm not sure a change to one necessarily implies a change is needed to the other. With Direct they may have initially followed the DCVax-L schedule, and now may realize they need a more aggressive one. Direct has a harder job to do outside the gate, it's dealing with massive tumors that haven't been removed. Shrinking those means a more robust and continuous army. Whereas DCVax-L, for the most part, is going after tumor remnants or cancer cells only. They won't need to space that schedule as close to do that task. I would think you would need to keep a further apart schedule in DCVax-L if there's no definitive evidence of immune memory. If Direct can prove immune memory, in future phases, then I do see them testing scheduling in DCVax-L to improve on efficacy results. But so far, and even as boosters point out, they might not be seeing immune memory; instead the use of booster may suggest that the vaccine needs to remain in the system to fight any recurring cells, particularly those left behind. But that's just my take.